Skip to main content
OpenTrials

Clinical trial condition

Indolent Systemic Mastocytosis

Explore clinical trials studying Indolent Systemic Mastocytosis. Study availability and eligibility vary by location and protocol.

9 public trials 3 recruiting studies
Refine in advanced search Browse all conditions

Indolent Systemic Mastocytosis trial results

Recruiting

(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis

NCT04910685

Conditions
Immune System Diseases, Indolent Systemic Mastocytosis, Mast Cell Activation Disorders, +7 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • David Geffen School of Medicine at UCLA Los Angeles, California, United States
  • Stanford Cancer Institute Palo Alto, California, United States
  • UCHealth Blood Disorders and Cell Therapies Center - Anschutz Medical Campus Aurora, Colorado, United States
View all 71 locations
View Trial Details
Recruiting

A Non-Interventional Study in Participants With Indolent Systemic Mastocytosis (ISM) in Germany

NCT07255638

Conditions
Immune System Diseases, Indolent Systemic Mastocytosis, Mast Cell Activation Disorders, +6 more
Locations
  • Charité Universitätmedizin Berlin, Klinik für Dermatologie, Venerologie und Allergologie Berlin, Germany
  • Katholisches Klinikum Bochum Bochum, Germany
  • MVZ Klinikum Deggendorf Deggendorf, Germany
  • Universitätsklinikum Carl Gustav Carus Dresden Klinik und Poliklinik für Dermatologie Dresden, Germany
View Trial Details
Completed

Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis

NCT00814073

Conditions
Albinism, Amino Acid Metabolism, Inborn Errors, Behavior, +28 more
Locations
  • UC Davis Health System , Department of Dermatology Sacramento, California, United States
  • MD Anderson Cancer Centre Houston, Texas, United States
  • CHU d'Amiens Amiens, France
  • Hôpital Avicenne Bobigny, France
View all 24 locations
View Trial Details
Completed

Treatment of Indolent Systemic Mastocytosis With PA101

NCT02478957

Conditions
Immune System Diseases, Indolent Systemic Mastocytosis, Mast Cell Activation Disorders, +7 more
Locations
  • Hopital Necker - Enfants Malades Paris, France
  • Charité - Universitätsmedizin Berlin Berlin, Germany
  • Klinikum Darmstadt Darmstadt, Germany
  • University Medical Center Mainz Mainz, Germany
View Trial Details
Active, Not Recruiting

(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis

NCT03731260

Conditions
Immune System Diseases, Indolent Systemic Mastocytosis, Mast Cell Activation Disorders, +6 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • Mayo Clinic Hospital Phoenix, Arizona, United States
  • Stanford Cancer Institute Stanford, California, United States
  • Mayo Clinic Florida Jacksonville, Florida, United States
View all 49 locations
View Trial Details

Related conditions